<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00226408</url>
  </required_header>
  <id_info>
    <org_study_id>MM-ADJ-5</org_study_id>
    <nct_id>NCT00226408</nct_id>
  </id_info>
  <brief_title>Standard High-Dose Alpha Interferon Versus Intermittent High-Dose Alpha Interferon</brief_title>
  <official_title>Randomized, Multicenter Study for Adjuvant Treatment of Stage III Malignant Melanoma: Intermittent, High-Dose Intravenous Interferon Alpha-2b Versus Standard High-Dose Interferon Alpha-2b Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermatologic Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermatologic Cooperative Oncology Group</source>
  <brief_summary>
    <textblock>
      The study protocol is being conducted to compare intermittent high-dose i.v. administation of
      interferon alpha-2b with the standard high-dose treatment by Kirkwood with distant metastasis
      free survival (DMFI) as a primary endpoint.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arm A: Interferon-alpha-2b 20 MIU/m2 for 4 weeks. 5 days a week i.v followed by 48 weeks of
      treatment with 3 x 10 MIU/m2 s.c Arm B: Interferon-alpha-2b 20 MIU/m2 for 4 weeks. 5 days a
      week i.v repeated 3 times with 12 treatment-free-weeks between the cycles

      Secondary endpoints: Improved overall survival rate, Assess side effects of therapy in both
      treatment arms, Assess time spent on sick leave, Assess number of treatment-related days in
      hospital, Assess overall performance status, Assess blood MX protein levels
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2003</start_date>
  <completion_date>September 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>distant metastasis free survival/(DMFI )</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity</measure>
  </secondary_outcome>
  <enrollment>600</enrollment>
  <condition>Adjuvant</condition>
  <condition>Stage III Malignant Melanoma</condition>
  <condition>Interferon Alpha</condition>
  <condition>Therapy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-alpha-2b</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological documentet cutaneous malognant melanoma

          -  Stage IIIa, IIIb, IIIc (AJCC 2002)

          -  R0 resection dating back no longer than 56 days

          -  Performance status (ECOG o-1)

          -  Bone marrow funktion: White cell count &gt; 3000 cells/ul, platletts &gt; 100000 cells/ul,
             hemoglobin &gt; 10 g/dl

          -  Liver and kidney funktion: Serum creatinin &lt; 1.5 times upper limit of normal, AST and
             ALT &lt; 2.5 times upper limit of normal, Serum bilirubin &lt; 2 times upper limit of normal

          -  Written inform consent

        Exclusion Criteria:

          -  Confirmed distant metastasis

          -  Choroid or mucosal melanoma

          -  Pregnant or lactating women and women of childbearing potential not using a reliable
             form of contraception

          -  Active autoimmun disease

          -  patients with history of neuropsychiatric disease requiring hospitalization

          -  Severe medical condition such us:

          -  Florid hepatitis

          -  Severe acute infection

          -  Myocardial infarction within the past year,symptomatic angina pectoris

          -  Grade III to IV congestive heart failure

          -  serious pulmonary disease

          -  HIV-positive patients with an AIDS - defining condition

          -  treatment in another clinical drug trial within the last 30 days

          -  A history of hypersensitivity to interferon alfa

          -  History of maignant disease during the past 5 years (except for curatively treated
             skin carcinoma or in situ carcinoma)

          -  Prior high dose interferon alfa therapy.Prior adjuvant low dose or intermediate-dose
             interferon alfa therapy is allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Mohr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Elbeklinikum, Buxtehude, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter von Wussow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>30159 Hannover,Georgstr.46</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Mohr, MD</last_name>
    <phone>0049 41261 703</phone>
    <phone_ext>6207</phone_ext>
    <email>p.mohr@elbekliniken.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Weichenthal, MD</last_name>
    <phone>0049 431 597</phone>
    <phone_ext>1537</phone_ext>
    <email>mweichenthal@dermatology.uni-kiel.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätshautklinik ,St.Josef- Hospital</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norbert Brockmeyer, MD</last_name>
      <phone>0049/234</phone>
      <phone_ext>509-1</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elbekliniken Buxtehude</name>
      <address>
        <city>Buxtehude</city>
        <zip>21614</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Miohr, MD</last_name>
      <phone>0049 4161 703</phone>
      <phone_ext>6207</phone_ext>
      <email>p.mohr@elbekliniken.de</email>
    </contact>
    <contact_backup>
      <last_name>michael weichenthal, MD</last_name>
      <phone>0049 431 597</phone>
      <phone_ext>1537</phone_ext>
      <email>mweichenthal@dermatolgy.uni-kiel.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätshautklinik Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Loquai, MD</last_name>
      <phone>0049/201-723</phone>
      <phone_ext>243</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karsten Neuber, MD</last_name>
      <phone>0049/42803</phone>
      <phone_ext>2632</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis</name>
      <address>
        <city>Hannover</city>
        <zip>30159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter von Wussow, MD</last_name>
      <phone>0049/511</phone>
      <phone_ext>3069998</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätshautklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Enk, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes, Hautklinik</name>
      <address>
        <city>Homburg/ Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Tilgen, MD</last_name>
      <phone>0049/6841-162</phone>
      <phone_ext>3966</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christian- Albrechts- Universität ,Hautklinik</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Hauschild, MD</last_name>
      <phone>0049/431-597</phone>
      <phone_ext>15</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätshautklinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Mauch, MD</last_name>
      <phone>0049/221478</phone>
      <phone_ext>537</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätshautklinik Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerstin Steinbrink, MD</last_name>
      <phone>0049/61311771</phone>
      <phone_ext>30</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>T. Luger, MD</last_name>
      <phone>0049/25183</phone>
      <phone_ext>56501</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtische Kliniken Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>261333</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erhard Hölzle, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätshautklinik Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cord Sunderkötter, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ADO-homepage.de</url>
  </link>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2005</study_first_submitted>
  <study_first_submitted_qc>September 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2005</study_first_posted>
  <last_update_submitted>June 20, 2006</last_update_submitted>
  <last_update_submitted_qc>June 20, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2006</last_update_posted>
  <keyword>melanoma,adjuvant therapy,stageIII Interferon</keyword>
  <keyword>high dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

